NVCT Earnings & Financial Statements
Nuvectis Pharma, Inc.
$18.93
+$0.93(+5.17%)
34
Overall
40
Value
30
Tech
34
Quality
Market Cap
$587.05M
Volume
156.86K
52W Range
$5.55 - $29.28
Target Price
$35.50
NVCT earnings and financial statements: Nuvectis Pharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NVCT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cost of revenue | $2.13M | $1.53M | $3.50M | $2.17M |
| Operating income | -$27.57M | -$19.85M | -$22.90M | -$19.23M |
| EBITDA | -$26.44M | -$19.00M | -$22.26M | -$19.23M |
| Net income | -$26.44M | -$19.00M | -$22.26M | -$19.09M |
| EPS (diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $31.71M | $18.61M | $19.18M | $20.41M |
| Total liabilities | $13.30M | $8.89M | $6.98M | $6.19M |
| Shareholders’ equity | $18.41M | $9.71M | $12.20M | $14.22M |
| Cash and equivalents | $31.60M | $18.53M | $19.13M | $19.99M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$16.01M | -$12.25M | -$15.95M | -$13.56M |
| Free cash flow | -$16.01M | -$12.25M | -$15.95M | -$13.56M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVCT | $18.93 | +5.2% | 156.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |